- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
AMLN
Banking on Buyouts in Biotech: Is It Smart?
Unless you really understand medicine, it's a very risky game. The chances of a little company scoring big and getting bought out are usually slim.
9 Biotech Buyout Players to Watch
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.
Manufacturing Woes Stop the Mo: Monday’s IP Market Recap
Markets reacted to a disappointing manufacturing report, starting out in negative territory before coming back for slight gains in the S&P and Nasdaq.
Should I Buy Bristol-Myers Squibb? 3 Pros, 3 Cons
Its deal to buy diabetes-drug maker Amylin will help, given that market's potential. Still, patent expirations loom large and won't be easily overcome.
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.
Q2: Second Verse, Just Like the First — Monday’s IP Market Recap
Second-quarter trading picks up where Q1 left off -- by advancing smartly on the first day of trading.
Here Comes a Bidding War for Amylin
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.
Amylin Perks Up on Rejection — Wednesday’s IP Market Recap
A spurned bid from Bristol-Myers Squibb sends AMLN up 54% on speculation that other offers will roll in.
‘Spam’ Linked to Diabetes in Native Americans
A new study raises questions about processed meat intake among Native Americans living on reservations and the development of diabetes.